Centre Europeen De Recherches Mauvernay

Akzo N.v.

Centre Europeen De Recherches Mauvernay 'cerm'

Riom Laboratoires C.e.r.m. 'rl-cerm' S.a.

Other

Riom Laboratories C.e.r.m.

Centre European De Recherches Mauvernay

Societe Anonyme Dite: Centre Europen De Recherches Mauvernay (c.e.r.m.)

Riom Laboratoires C.e.r.m.

Andre J Monteil

Jacques A Simond

Jacques Moleyre

Norbert Busch

Roland Yves Mauvernay

Patrick Carlier

Michel Combourieu

Claude Poisson

Roland-Yves Mauvernay

Norbert Bush

Roland Yves Mauvernary

Jacques Simons

Jacques Simond

The invention relates to neuroleptic/antidepressant 4-[4- or 6-(trifluoromethyl)-2-pyridinyl]-1-piperazinylalkyl substituted lactam derivatives having the general structure of formula I: ##STR1## wherein one of the groups R.sub.1 and R.sub.2 is CF.sub.3, and the other is hydrogen or CF.sub.3 ;

4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinylalkyl substituted

Disclosed are compounds displaying improved preferential serotonin-1A binding activity. The claimed compounds have the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of hydroxy, halogen, lower alkyl, lower alkoxy, and hydrogen;

Pyridinylpiperazine derivatives

Pharmaceutical composition which is useful as a medicinal product, in particular for the treatment of disorders of the central nervous system, characterized in that it contains customary pharmaceutical excipients, and at least one of the compounds of formula ##STR1## in which the trifluoromethyl substituent is at the 4-position, at the 5-position, or at 4- and 5-positions of the pyridinyl ring, and the substituent R denotes either hydrogen or a halogen, such as chlorine, at position(s) of the pyridinyl ring not occupied by CF.sub.3, and its pharmaceutically acceptable salts.

Pharmaceutical composition containing 1-(mono- or

Compounds of formula: ##STR1## in which R and R' each denote an alkyl or cycloalkyl radical having 1 to 7 carbon atoms; X denotes --O-- or H.sub.2 ; and Y and Z denote hydrogen or one or more radicals chosen from halogeno, hydroxy, straight or branched alkyl having 1 to 6 carbon atoms, alkoxy having 1 to 6 carbon atoms, trifluoromethyl or methylenedioxy; n being able to assume the values 2 or 3; and their pharmaceutically acceptable salts. Application as a cardiovascular medicinal product.

Substituted 3-piperidinamines or 3-azepinamines, the preparation thereof

Compounds of formula: ##STR1## in which R and R' denote an alkyl radical having 1 to 7 carbon atoms; R.sub.1 denotes hydrogen or an alkyl radical having 1 to 7 carbon atoms; and R.sub.2 and R.sub.3 denote, separately, an alkyl radical having 1 to 7 carbon atoms or a phenyl radical, or, together with the carbon atom to which they are attached, a cycloalkyl radical having at most 7 carbon atoms; n may assume the values 2 or 3; and their pharmaceutically acceptable salts. Application as a cardiovascular medicinal product.

New substituted piperidine or azepine compounds which have useful

The present invention relates to new compounds of the general formula: ##STR1## in which Ar represents thienyl, furyl, pyridyl or an optionally substituted phenyl group,

3-alkoxy-2-(N-pyrrolidino)-N-pyrimidinyl- or -N-pyrazinolpropylamines

Compounds of the formula: ##STR1## in which X represents one or two radicals selected from halogen, hydroxyl, alkoxy, alkyl, trifluoromethyl or methylenedioxy radicals, and their pharmaceutically acceptable salts, which may be used in the treatment of cardiovascular disturbances such as angina pectoris, hypertension and rhythmic disorders.

2-(N-pyrrolidino)-3-isobutoxy-n-substituted-phenyl-n-benzyl-propylamines,

The present invention relates to new compounds of the general formula: ##STR1## in which X represents oxygen or sulphur and R represents a linear or branched alkyl group with 1 to 7 carbon atoms, and pharmaceutically acceptable acid addition salts thereof, having valuable cardiovascular properties.

3-Alkoxy-2-(N-pyrolidino)-N-pyridyl-N-furyl(or thienyl) methyl-pyropyl

The invention is dealing with compounds of the formula: ##STR1## and pharmaceutically acceptable salts thereof, in which R.sub.1 and R.sub.2 each represent a lower alkyl radical or a phenyl radical, or, together with the carbon atom to which they are bound, a cycloalkyl radical having at the most 7 carbon atoms; R.sub.3 represents hydrogen, a lower alkyl radical, or the phenyl radical; R.sub.4 and R.sub.5 each represent a lower alkyl radical, or, together with the nitrogen atom to which they are bound, a heterocyclic amino radical such as the pyrrolidinyl or morpholino radicals; and R.sub.6 represents a lower alkyl radical, a phenyl radical, a benzyl radical, or the 1-ethynyl-cyclohexyl radical, which compounds can be used in the treatment of angina pectoris.

Ethers of 1-(2-propynyloxy)-2-amino-3-propanol

The invention relates to novel 6-aryloxy-2-oxo-1-aza-4-(or thia)-spiro[4,5]decane compounds. These compounds are represented by the formula: ##STR1## in which A stands for an oxygen or sulfur heteroatom; R.sub.1 and R.sub.2 are each H, lower alkyl or aryl such as phenyl; X is H, a halogen atom such as chlorine or fluorine or a lower alkyl. Compounds according to the invention are useful as stimulating agents for vigilance, as psycho-stimulators and genesic stimulators.

Certain 6-aryloxy-2-oxo-1-aza-4-thia-spiro[4,5]decanes

2-(2-Hydroxyethyl)tetrahydro-1,4-oxazines and quaternary salts thereof having the formula: ##STR1## WHEREIN Ar and Ar.sub.1 are the same or different and are unsubstituted and substituted aryl, said substituent being a halogen atom, R represents a lower alkyl group having from 1 to 4 carbon atoms, R.sub.1 is zero when X.sup.(-) is zero or is an alkyl group of from 1 to 4 carbon atoms which is the same or different from R, as defined above, and X.sup.(-) is zero when R.sub.1 is zero or is selected from the group consisting of Cl.sup.(-), Br.sup.(-), I.sup.(-) and CH.sub.3 SO.sub.4.sup.(-) when R.sub.1 is lower alkyl, as defined above, is described. These compounds are useful for treating spasmodic syndromes.

Substituted 2-(2-hydroxyethyl)tetrahydro-1,4 oxazines and quaternary

Compounds of the formula: ##STR1## wherein R is a lower alkyl group, X is oxygen or the group --(CH.sub.2).sub.n -- where n is 0 or 1, having bronchospasmolytic activity, are described.

Pharmaceutically active compounds and the preparation thereof

Compounds of the formula ##STR1## and pharmaceutically acceptable acid salts thereof, wherein X is hydrogen, halogen or methoxy, n is zero, Y is halogen and the ethyl piperazaine moiety is attached to the 2- or 4- position of the piperidine ring, is described. These compounds have anti-spasmolytic and antitussive activity.

1-Benzoyl-2 or 4 [2-(4-phenyl-piperazino)-ethyl]-piperidines

This invention relates to a new group of substituted cysteines having the general formula: ##STR1## in which: Ar is an aromatic or heteromonocyclic group, such as 2-thienyl or phenyl, which may be substituted by a halogen atom or by a lower alkyl or alkoxy group, and R is a hydrogen atom or a lower alkyl group. These compounds are of use in human therapeutics as liquifiers for bronchal secretions in complaints of the respiratory passage and, in particular, in chronic bronchitis. The invention also relates to a method of preparing these compounds and to the application of these compounds, particularly in human therapeutics.

Substituted cysteines

Novel compounds, certain 3-aryloxy-2-hydroxy-cyclohexyl-amines, having vable pharmacological properties e.g. antidepressant activity are described together with a process for their preparation, pharmaceutical compositions thereof and a method of treatment involving their use.

Growing community of inventors

Chatel-Guyon, France

Andre J Monteil